Skip to content

Buy Generic Soma Carisoprodol

Product Name Price Order link
Carisoprodol (Soma Generic) 350mg – 30 Tabs $45
Carisoprodol (Soma Generic) 350mg – 90 Tabs $70
Soma 350mg – 30 Tabs ( Watson Brand ) $50
Soma 350mg – 90 Tabs ( Watson Brand ) $75
Butalbital/APAP/Caffeine – 30 Tabs $50
Butalbital/APAP/Caffeine – 90 Tabs $65
Fioricet – 30 Tabs $85
Fioricet – 90 Tabs $183
Tramadol 50mg – 30 Tabs $50
Tramadol 50mg – 90 Tabs $65
Tramadol 50mg – 180 Tabs $99

Carisoprodol tablets are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults.  Carisoprodol is a muscle relaxer that works by blocking pain sensations between the nerves and the brain. Carisoprodol is used together with rest and physical therapy to treat injuries and other painful musculoskeletal conditions.

Carisoprodol tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration.

What special precautions should I follow?  

Before taking carisoprodol,

  • tell your doctor and pharmacist if you are allergic to carisoprodol, meprobamate (Equanil, Meprospan, Miltown, Neuramate), or any other drugs.
  • tell your doctor and pharmacist what prescription and nonprescription medications you are taking, especially medications for allergies, coughs, or colds; muscle relaxants; sedatives; sleeping pills; tranquilizers; and vitamins.
  • tell your doctor if you have or have ever had kidney or liver disease.
  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking carisoprodol, call your doctor.
  • you should know that this drug may make you drowsy. Do not drive a car or operate machinery until you know how carisoprodol affects you.
  • remember that alcohol can add to the drowsiness caused by this drug.

Carisoprodol may be habit-forming and should be used only by the person it was prescribed for. Carisoprodol should never be given to another person, especially someone who has a history of drug abuse or addiction. Keep the medication in a secure place where others cannot get to it. You may have withdrawal symptoms when you stop using carisoprodol after using it over a long period of time. Do not stop using this medication suddenly without first talking to your doctor. You may need to use less and less before you stop the medication completely. Carisoprodol can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert. Avoid drinking alcohol. It can increase drowsiness and dizziness caused by carisoprodol.

Do not use Carisoprodol ( Generic Soma ) if you are allergic to carisoprodol or meprobamate (Equanil, Miltown), or if you have porphyria.
Before using Carisoprodol ( Generic Soma ), tell your doctor if you are allergic to any drugs, or if you have:

epilepsy or other seizure disorder;

liver disease; or

kidney disease.

If you have any of these conditions, you may need a dose adjustment or special tests to safely take carisoprodol.

Carisoprodol ( Generic Soma ) may be habit-forming and should be used only by the person it was prescribed for. Carisoprodol should never be given to another person, especially someone who has a history of drug abuse or addiction. Keep the medication in a secure place where others cannot get to it. You may have withdrawal symptoms when you stop using carisoprodol after using it over a long period of time. Withdrawal symptoms include stomach pain, sleep problems, headache, nausea, and seizure (convulsions). Do not stop using Carisoprodol ( Generic Soma ) suddenly without first talking to your doctor. You may need to use less and less before you stop the medication completely. Carisoprodol ( Generic Soma ) may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether carisoprodol passes into breast milk or if it could harm a nursing baby. Do not use Carisoprodol ( Generic Soma ) without telling your doctor if you are breast-feeding a baby. Do not give Carisoprodol ( Generic Soma ) to a child younger than 12 years old..

Carisoprodol side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using carisoprodol and call your doctor at once if you have any of these serious side effects:

  • paralysis (loss of feeling);
  • extreme weakness or lack of coordination;
  • feeling light-headed, fainting;
  • fast heartbeat;
  • seizure (convulsions);
  • vision loss; or
  • agitation, confusion.

Less serious side effects may include:

  • drowsiness, dizziness, tremor;
  • headache;
  • depression, feeling irritable;
  • blurred vision;
  • sleep problems (insomnia); or
  • nausea, vomiting, hiccups, upset stomach.

Carisoprodol Sedation

SOMA has sedative properties (in the low back pain trials, 13% to 17% of patients who received SOMA experienced sedation compared to 6% of patients who received placebo) and may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a motor vehicle or operating machinery. There have been post-marketing reports of motor vehicle accidents associated with the use of SOMA.

Since the sedative effects of SOMA and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously.

Carisoprodol Generic Soma Drug Dependence, Withdrawal, and Abuse

In the postmarketing experience with SOMA, cases of dependence, withdrawal, and abuse have been reported with prolonged use. Most cases of dependence, withdrawal, and abuse occurred in patients who have had a history of addiction or who used SOMA in combination with other drugs with abuse potential. However, there have been post-marketing adverse event reports of SOMA-associated abuse when used without other drugs with abuse potential. Withdrawal symptoms have been reported following abrupt cessation after prolonged use. To reduce the chance of SOMA dependence, withdrawal, or abuse, SOMA should be used with caution in addiction-prone patients and in patients taking other CNS depressants including alcohol, and SOMA should not be used more than two to three weeks for the relief of acute musculoskeletal discomfort.

SOMA, and one of its metabolites, meprobamate (a controlled substance), may cause dependence.

Seizures because of Carisoprodol

There have been postmarketing reports of seizures in patients who received SOMA. Most of these cases have occurred in the setting of multiple drug overdoses (including drugs of abuse, illegal drugs, and alcohol).

Nonclinical Toxicology of Carisoprodol

Carcinogenesis, Mutagenesis, Impairment of Fertility of Carisoprodol

Long term studies in animals have not been performed to evaluate the carcinogenic potential of carisoprodol.

SOMA was not formally evaluated for genotoxicity. In published studies, carisoprodol was mutagenic in the in vitro mouse lymphoma cell assay in the absence of metabolizing enzymes, but was not mutagenic in the presence of metabolizing enzymes. Carisoprodol was clastogenic in the in vitro chromosomal aberration assay using Chinese hamster ovary cells with or without the presence of metabolizing enzymes. Other types of genotoxic tests resulted in negative findings. Carisoprodol was not mutagenic in the Ames reverse mutation assay using S. typhimurium strains with or without metabolizing enzymes, and was not clastogenic in an in vivo mouse micronucleus assay of circulating blood cells.

SOMA was not formally evaluated for effects on fertility. Published reproductive studies of carisoprodol in mice found no alteration in fertility although an alteration in reproductive cycles characterized by a greater time spent in estrus was observed at a carisoprodol dose of 1200 mg/kg/day. In a 13-week toxicology study that did not determine fertility, mouse testes weight and sperm motility were reduced at a dose of 1200 mg/kg/day. In both studies, the no effect level was 750 mg/kg/day, corresponding to approximately 2.6 times the human equivalent dosage of 350 mg four times a day, based on a body surface area comparison. The significance of these findings for human fertility is not known.

Carisoprodol Use In Specific Population

Carisoprodol for Pregnancy: Pregnancy Category C.

There are no data on the use of SOMA during human pregnancy. Animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival. The primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic. Retrospective, post-marketing studies do not show a consistent association between maternal use of meprobamate and an increased risk for particular congenital malformations.

Teratogenic effects

Animal studies have not adequately evaluated the teratogenic effects of carisoprodol. There was no increase in the incidence of congenital malformations noted in reproductive studies in rats, rabbits, and mice treated with meprobamate. Retrospective, post-marketing studies of meprobamate during human pregnancy were equivocal for demonstrating an increased risk of congenital malformations following first trimester exposure. Across studies that indicated an increased risk, the types of malformations were inconsistent.

Nonteratogenic effects

In animal studies, carisoprodol reduced fetal weights, postnatal weight gain, and postnatal survival at maternal doses equivalent to 1-1.5 times the human dose (based on a body surface area comparison). Rats exposed to meprobamate in-utero showed behavioral alterations that persisted into adulthood. For children exposed to meprobamate in-utero, one study found no adverse effects on mental or motor development or IQ scores. SOMA should be used during pregnancy only if the potential benefit justifies the risk to the fetus.

the effects of SOMA for Labor and Delivery

There is no information about the effects of SOMA on the mother and the fetus during labor and delivery.

the effects of SOMA for Nursing Mothers

Very limited data in humans show that SOMA is present in breast milk and may reach concentrations two to four times the maternal plasma concentrations. In one case report, a breast fed infant received about 4-6% of the maternal daily dose through breast milk and experienced no adverse effects. However, milk production was inadequate and the baby was supplemented with formula. In lactation studies in mice, female pup survival and pup weight at weaning were decreased. This information suggests that maternal use of SOMA may lead to reduced or less effective infant feeding (due to sedation) and/or decreased milk production. Caution should be exercised when SOMA is administered to a nursing woman.

Pediatric Use

The efficacy, safety, and pharmacokinetics of SOMA in pediatric patients less than 16 years of age have not been established.

Geriatric Use

The efficacy, safety, and pharmacokinetics of SOMA in patients over 65 years old have not been established.

Renal Impairment

The safety and pharmacokinetics of SOMA in patients with renal impairment have not been evaluated. Since SOMA is excreted by the kidney, caution should be exercised if SOMA is administered to patients with impaired renal function. Carisoprodol is dialyzable by hemodialysis and peritoneal dialysis.

Hepatic Impairment

The safety and pharmacokinetics of SOMA in patients with hepatic impairment have not been evaluated. Since SOMA is metabolized in the liver, caution should be exercised if SOMA is administered to patients with impaired hepatic function.

Patients with Reduced CYP2C19 Activity

Patients with reduced CYP2C19 activity have higher exposure to carisoprodol. Therefore, caution should be exercised in administration of SOMA to these patients.